CANCER
The Comprehensive Cancer Panels encompass 153 genes linked to the potential susceptibility for hereditary cancer syndromes. These panels consist of established genes associated with cancer as well as newly identified candidate genes with potential cancer associations, albeit with uncertain or diminished risk. Individuals and families presenting with intricate conditions might find enhanced utility in more exhaustive testing. Our Comprehensive Cancer Panels aim to optimize the detection of disease-causing variations and offer a thorough assessment of potential cancer susceptibilities arising from supplementary candidate genes.
The Complete Comprehensive Cancer Panel evaluates 153 genes linked to hereditary cancer. It encompasses established genes known to elevate cancer risk, alongside candidate genes that may have recently emerged or require further investigation. By doing so, this panel enhances the likelihood of detecting a cancer susceptibility variant, while offering an in-depth examination of candidate genes to furnish both immediate and potential future insights.
Am I a candidate for this test?
Adults exhibiting personal or familial indications suggestive of a hereditary cancer syndrome may benefit from this testing. Indicators for a hereditary cancer predisposition may include cancer onset before the age of 50, occurrence of multiple primary cancers in one individual, and presence of multiple affected individuals within a family. Following assessment of both clinical and familial history, consideration of this testing may also be relevant for certain pediatric patients. Specific genes to be excluded can be noted on the test requisition form, if necessary. This test is aimed at identifying individuals with a hereditary pathogenic variant in their germline and is not validated for detecting mosaicism below a 20% threshold. It is not suitable for ordering on tumor tissue.
How can your patient benefit from it?
Patients diagnosed with hereditary cancer susceptibility stand to gain from heightened surveillance and preventive measures to effectively mitigate their cancer risk. Identifying the precise gene implicated can inform medical management and prevent unwarranted follow-ups. Insights gleaned from candidate gene testing could prove invaluable in shaping future clinical approaches. Furthermore, testing family members of the patient can aid in delineating their risk profile. Should a pathogenic variant be detected in the patient, close relatives (such as children, siblings, and parents) may have up to a 50% chance of sharing the heightened risk. In certain scenarios, screening may even need to commence during childhood.